Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TriLink to Open New Early Phase Therapeutic Manufacturing Facility

Published: Tuesday, May 27, 2014
Last Updated: Tuesday, May 27, 2014
Bookmark and Share
Company's new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014.

TriLink BioTechnologies’ new facility will feature validated ISO Class 7 and ISO Class 8 clean rooms, specifically designed to facilitate fast turnaround of IND-enabling tox and Phase 0/I GMP material. 

TriLink decided to build the facility to meet the growing demand for therapeutic grade GMP mRNA. However, the new facility is fully equipped to manufacture all TriLink products including long RNA, aptamers, oligonucleotides, small molecules and nucleoside triphosphates. Because TriLink’s GMP quality system is specifically designed for early phase materials the service will also be a more economical choice for customers investigating safety and efficacy.

“Building a GMP facility was a natural expansion of our business and leveraged our well-established quality system. TriLink has been at the forefront of the rapidly emerging mRNA market. It was through customer’s inquiries we learned of the need for a supplier of therapeutic grade mRNA and the rest just fell into place,” said Terry Beck, Sr. Vice President.                   

"Our existing quality system, agile business model and extensive nucleic acid synthesis experience place us in a prime position to provide affordable IND and Phase I materials fast," said CEO, Richard Hogrefe, Ph.D. "We hope this new service provides an avenue for more nucleic acid based drugs to make it to the clinic."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TriLink Announces New License Agreement with Biofortuna
Agreement for use of CleanAmp™ dNTPs in Biofortuna’s freeze-drying contract development and production service.
Friday, November 08, 2013
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.
Thursday, May 16, 2013
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
TriLink BioTechnologies Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.
Thursday, May 09, 2013
TriLink BioTechnologies, Inc. Awarded European Patent
TriLink BioTechnologies, Inc. announces the award of their CleanAmp™ Primer patent by the European Patent Office (EPO Patent no. 2032714).
Tuesday, May 31, 2011
TriLink BioTechnologies, Inc. Announces License Agreement with Biofortuna Ltd
TriLink BioTechnologies, announced that it has signed a licensing agreement with Biofortuna Ltd. for use of CleanAmp™ dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits.
Tuesday, September 14, 2010
TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity
The National Institutes of Health recently awarded TriLink BioTechnologies, Inc. (TriLink) a Phase II SBIR Grant of approximately $725,000 to continue their work on developing reagents to enhance the specificity of DNA ligase.
Tuesday, June 22, 2010
TriLink BioTechnologies, Inc. Announces Supply Agreement with ETS Laboratories
TriLink BioTechnologies, Inc. (TriLink) announced that it has signed an agreement with ETS Laboratories (ETS) to supply CleanAmp™ dNTPs for use in their Scorpions™ Wine Spoilage Detection System.
Tuesday, April 27, 2010
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!